Assembly biosciences to present data from hbv core inhibitor programs at the international liver congress™ easl 2021

South san francisco, calif., june 09, 2021 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis b virus (hbv), today announced that three abstracts have been accepted for presentation during the international liver congress™ 2021, the annual meeting of the european association for the study of the liver (easl) taking place virtually june 23-26, 2021. during the meeting, data from assembly bio's three core inhibitor programs, vebicorvir (vbr), abi-h2158 (2158) and abi-h3733 (3733), will be featured in an oral presentation and two poster presentations.
ASMB Ratings Summary
ASMB Quant Ranking